Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 2997-3006

  Frühwald, Michael C ^a   Rickert, Christian H ^a,b   O'Dorisio, M Sue ^c   Madsen, Mark ^d   Warmuth Metz, Monika ^e   Khanna, Geetika ^d   Paulus, Werner ^a   Kühl, Joachim ^e   Jürgens, Heribert ^a   Schneider, Peter ^f   Müller, Hermann L ^g  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g KLINIKUM OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR 2;

ADOLESCENT; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; INFANT; MALE; MINIMAL RESIDUAL DISEASE; NEUROECTODERM TUMOR; NEUROEPITHELIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TERATOMA; TUMOR DIFFERENTIATION; TUMOR RECURRENCE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE; RECEPTORS, SOMATOSTATIN; SUPRATENTORIAL NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 2442421985     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0083     Document Type: Article

References (40)

1. Gilbertson R. Paediatric embryonic brain tumours. Biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002;38:675-85.
2. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61:215-25.
3. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol & Exp Neurol 1983; 42:1-15.
4. Rorke LB, Trojanowski JQ, Lee VM, et al. Primitive neuroectodermal tumors of the central nervous system. Brain Pathol 1997;7:765-84.
5. Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 2002;20:842-9.
6. Albright AL, Wisoff JH, Zeltzer P, et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 1995;22:1-7.
7. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994;330:892-5.
8. Steinbok P, Hentschel S, Cochrane DD, Kestle JR. Value of postoperative surveillance imaging in the management of children with some common brain tumors. J Neurosurg 1996;84:726-32.
9. Korones DN, Butterfield R, Meyers SP, Constine LS. The role of surveillance magnetic resonance imaging (MRI) scanning in detecting recurrent brain tumors in asymptomatic children. J Neuro-Oncol 2001; 53:33-8.
10. Kramer ED, Vezina LG, Packer RJ, et al. Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children's Cancer Group. Pediatr Neurosurg 1994;20:254-62.
11. Erdem E, Zimmerman RA, Haselgrove JC, Bilaniuk LT, Hunter JV. Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroradiology 2001;43:927-33.
12. Müller HL, Frühwald MC, Scheubeck M, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neuro-Oncol 1998;38:27-40.
13. Frühwald MC, O'Dorisio MS, Pietsch T, Reubi JC. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res 1999;45:697-708.
14. Albers AR, O'Dorisio MS, Balster DA, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000;88:61-73.
15. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002; 13:451-7.
16. Schindler M, Holloway S, Humphrey PP, et al. Localization of the somatostatin sst2(a) receptor in human cerebral cortex, hippocampus and cerebellum. Neuroreport 1998;9:521-5.
17. Frühwald MC, O'Dorisio MS, Pietsch T, Reubi JC. Receptors for somatostatin (sms) and vasoactive intestinal peptide (VIP) in medulloblastoma as diagnostic and therapeutic targets. Neuro-Oncol 1999;1:19.
18. Graham ML, Herndon JE II, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814-23.
19. Gururangan S, McLaughlin C, Quinn J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 2003;21:2187-91.
20. Russo C, Pellarin M, Tingby O, et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer (Phila) 1999;86:331-9.
21. Frühwald MC, O'Dorisio MS, Dai Z, et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 2001; 30:38-47.
22. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
23. Cervera P, Videau C, Viollet C, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol 2002;14:458:71.
24. Guyotat J, Champier J, Jouvet A, et al. Differential expression of somatostatin receptors in ependymoma: implications for diagnosis. Int J Cancer 2001;95:144-51.
25. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000;85:3882-91.
26. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24:28-47.
27. Feindt J, Becker I, Blomer U, et al. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 1995;65:1997-2005.
28. Haldemann AR, Rosler H, Barth A, et al. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 1995;36:403-10.
29. Meewes C, Bohuslavizki KH, Krisch B, et al. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med 2001;42:1338-45.
30. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
31. Kiaris H, Schally AV, Nagy A, et al. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 2000;6:709-17.
32. Vaidyanathan G, Friedman HS, Affleck DJ, et al. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 2003;9:1868-76.
33. Merlo A, Hausmann O, Wasner M, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33.
34. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002;24:337-42.
35. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-64.
36. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 1994;54:5895-901.
37. Luyken C, Hildebrandt G, Scheidhauer K, et al. 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir 1994;127:60-4.
38. Lamszus K, Meyerhof W, Westphal M. Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas. J Neuro-Oncol 1997;35:353-64.
39. Sure U, Ruedi D, Tachibana O, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol & Exp Neurol 1997;56:782-9.
40. Maini CL, Sciuto R, Tofani A, et al. Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nucl Med Commun 1995;16: 756-66.